The AACR Grantee Summit 2026: Fueling Discovery and Fostering Connection
The recent AACR Grantee Summit showcased the impactful research funded by AACR grants, including new targeted therapy approaches, miniaturized...
Tag: Antibody-drug conjugates
The recent AACR Grantee Summit showcased the impactful research funded by AACR grants, including new targeted therapy approaches, miniaturized...
In the latest edition of From the Bench, the AACR Blog explores recent innovative approaches to cancer research, including...
The fall issue of Cancer Today explores treatment advances for people with multiple myeloma whose cancer has returned or...
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New...
Antibody-drug conjugates, or ADCs, are increasingly common cancer therapies. But what are they? How do they work? And how...
We highlight some of the many innovations showcased at the inaugural AACR Drug Discovery and Development (AACR D3) conference,...
The AACR D3 edition of “From the Bench” highlights cutting-edge approaches from the meeting that could shape the next...
The FDA issued 14 oncology approvals this quarter, including the first tumor-infiltrating lymphocyte therapy.
In part 3 of our 2024 Experts Forecast, AACR President-Elect Patricia M. LoRusso, DO, PhD (hc), FAACR, shares thoughts...
Guest Post by William G. Nelson, MD, PhD, Editor-in-Chief, Cancer Today Many argue that warfare metaphors, with winners and losers,...